Linkage to Care and Treatment of Chronic HBV Patients

NCT06658678 | Completed

• 1 other identifier: HBVcare
• Study Type: interventional
• Target: 803
• Locations: 1 country
• Sites: 1

Brief Summary

Chronic hepatitis B remains the leading cause of liver related mortality and morbidity globally and locally. Countries have been formulating initiatives to meet the WHO target of eliminating viral hepatitis by 2030. However, data on the most important aspect of management of chronic hepatitis B, namely linkage to care and treatment, remains scarce. In order to achieve the WHO goal, treatment rate of eligible patients should reach 80%.

Conditions

Hepatitis B, Chronic

Outcome Measures

Primary Outcomes (1)

• The effect of education intervention on rate of retention in care in chronic hepatitis B patients identified from a territory wide screening program

  12 months

Secondary Outcomes (4)

• The treatment rate in chronic hepatitis B patients up to 5 years after diagnosis

  5 years

• The rate of viral suppression in chronic hepatitis B patients up to 5 years after diagnosis

  5 years

• The rate of complication in chronic hepatitis B patients up to 5 years after diagnosis

  5 years

• Factors affecting rate of retention in care from patient perspective in the form of questionnaire survey

  12 months

Study Arms (2)

Receiving an educational intervention

EXPERIMENTAL

Receiving the educational video link on their mobile device

Other: Receiving an educational intervention

No educational intervention

NO INTERVENTION

Interventions

Receiving an educational intervention OTHER

Patient not receiving any educational intervention

Also known as: No educational intervention

Receiving an educational intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• CHB (HBV DNA+ or HBsAg+ for more than 6 months)
• Age \>18
• Treatment naive at initial presentation

You may not qualify if:

• Prior HBV treatment
• Organ transplant or other immunosuppression
• HIV, HDV, HCV co-infection
• Decompensated or HCC patients

Sponsors & Collaborators

• The University of Hong Kong: lead

Study Sites (1)

Department of Medicine and Department of Surgery, The University of Hong Kong, Queen Mary Hospital

Hong Kong, Hong Kong

Location

MeSH Terms

Conditions

Hepatitis B, Chronic

Condition Hierarchy (Ancestors)

Hepatitis B; Blood-Borne Infections; Communicable Diseases; Infections; Hepadnaviridae Infections; DNA Virus Infections; Virus Diseases; Hepatitis, Viral, Human; Hepatitis, Chronic; Hepatitis; Liver Diseases; Digestive System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: SCREENING
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professor

Study Record Dates

• First Submitted: June 25, 2024
• First Posted: October 26, 2024
• Study Start: April 3, 2021
• Primary Completion: December 31, 2021
• Study Completion: December 31, 2022
• Last Updated: October 26, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

HK (1)